Bio-Rad last week reported a 3 percent uptick in fourth-quarter 2011 revenues in its overall business and Life Science segment, the latter driven primarily by strong sales in its core markets of electrophoresis, imaging, and real-time PCR-based gene expression.

In addition, Bio-Rad executives said that the digital PCR platform the company acquired in October along with biotech firm QuantaLife is expected to generate $20 million in sales in 2012; and that an increased investment in the platform would likely also drive up R&D costs at the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.